AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31060535 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight, body composition and energy balance related behaviours (EBRB) assessment at four occasions (12 weeks of pregnancy, 6 weeks postpartum, 6 months postpartum, and 12 months postpartum)
Number of subjects: 0
Study 31060535 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake, physical activity, sedentary behaviour, smoking habits, sleeping pattern, fatigue, diet and exercise related partner support, mental health, breastfeeding, contraception use, and socio-demographics assessed via questionnaire
Number of subjects: 0
Study 31060535 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry for objective assessment of physical activity and sedentary behaviour
Number of subjects: 0
Study 31060535 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from women's medical records including pre-pregnancy weight and pregnancy outcomes
Number of subjects: 0
Study 31060562 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 intake < 1.7 g/day
Number of subjects: 421
Study 31060567 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H5N1 vaccine (2-dose vaccination schedule)
Number of subjects: 50
Study 31060612 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel (C + P) chemotherapy followed by HPV16-E7 synthetic long peptide (E7LP) vaccination
Number of subjects: 0
Study 31060612 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-therapy: C + P chemotherapy, E7LP vaccination, and intravaginal CpG
Number of subjects: 0
Study 31060612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoparticle-conjugated E7LP vaccine
Number of subjects: 0
Study 31061018 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (SSBs)
Number of subjects: 154289
Study 31061018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit juice
Number of subjects: 154289
Study 31061018 — intervention group
Group type: COMPARATOR
Intervention: Fruit intake
Number of subjects: 154289
Study 31061035 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent binge drinking between the age of 18 and 25 years (defined as more than twice a month)
Number of subjects: 166
Study 31061035 — intervention group
Group type: COMPARATOR
Intervention: No binge drinking (control group)
Number of subjects: 166
Study 31061035 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent binge drinking between the age of 18 and 25 years
Number of subjects: 166
Study 31061058 — intervention group
Group type: EXPERIMENTAL
Intervention: Care according to national and international guidelines during hospitalisation and follow-up for 6 months after discharge.
Number of subjects: 0
Study 31061063 — intervention group
Group type: EXPERIMENTAL
Intervention: WYZ mobile health application
Number of subjects: 76
Study 31061061 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood type A/AB
Number of subjects: 3417
Study 31061061 — intervention group
Group type: COMPARATOR
Intervention: Blood type B/O
Number of subjects: 3417
Study 31061070 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monotherapy
Number of subjects: 19
Study 31061070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral IL17-mediated signaling
Number of subjects: 19
Study 31061070 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of drugs targeting the IL17 signaling pathway with T-cell checkpoint inhibitors
Number of subjects: 19
Study 31061107 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail patients (assessed using the FRAIL Scale)
Number of subjects: 116
Study 31061107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrusive preoperative pain
Number of subjects: 116
Study 31061107 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine surgery
Number of subjects: 116
Study 31061425 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (exact dosage and duration not specified)
Number of subjects: 0
Study 31061425 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 31061681 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary TIMP2∗IGFBP7 concentration > 2.0 (ng/ml)
Number of subjects: 112
Study 31061783 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Primary School of the Future intervention
Number of subjects: 0
Study 31061783 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 0
Study 31061783 — intervention group
Group type: EXPERIMENTAL
Intervention: External sources
Number of subjects: 0
Study 31061876 — intervention group
Group type: EXPERIMENTAL
Intervention: Xlimus sirolimus-eluting stent (SES)
Number of subjects: 180
Study 31061876 — intervention group
Group type: COMPARATOR
Intervention: Synergy everolimus-eluting stent (EES)
Number of subjects: 180
Study 31062066 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Prostate Artery Embolization (PAE)
Number of subjects: 15
Study 31062066 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 15
Study 31062234 — intervention group
Group type: EXPERIMENTAL
Intervention: oCRH administration
Number of subjects: 27
Study 31062633 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape/pomegranate pomace dietary supplement
Number of subjects: 0
Study 31062633 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31062760 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with HFpEF
Number of subjects: 1065
Study 31062760 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1065
Study 31062760 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 1065
Study 31063537 — intervention group
Group type: EXPERIMENTAL
Intervention: cART based on 2 nucleoside reverse transcriptase inhibitors plus 1 ritonavir-boosted protease inhibitor
Number of subjects: 141
Study 31063862 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab, 1500 mg every 4 weeks, and Olaparib, 300 mg twice a day
Number of subjects: 20
Study 31064390 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation facilitation (IF)
Number of subjects: 120
Study 31064390 — intervention group
Group type: COMPARATOR
Intervention: Standard educational dissemination strategy
Number of subjects: 120
Study 31064595 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifactor latent variable approach for measuring irritability and anxiety
Number of subjects: 331
Study 31064595 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported irritability and anxiety factors
Number of subjects: 331
Study 31064595 — intervention group
Group type: EXPERIMENTAL
Intervention: General negative affectivity factor
Number of subjects: 331
Study 31064750 — intervention group
Group type: EXPERIMENTAL
Intervention: White patients with HVLPD
Number of subjects: 16
Study 31064750 — intervention group
Group type: COMPARATOR
Intervention: Nonwhite patients with HVLPD
Number of subjects: 16
Study 31064781 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 2287411 (mesothelin-targeted thorium-227 conjugate)
Number of subjects: 0
Study 31064851 — intervention group
Group type: EXPERIMENTAL
Intervention: SY-1365, a selective CDK7 inhibitor
Number of subjects: 0
Study 31065301 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics added to antimicrobial treatment
Number of subjects: 56
Study 31065301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 31065384 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC PM® with Macintosh Blade
Number of subjects: 0
Study 31065384 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC PM® with D-Blade®
Number of subjects: 0
Study 31065624 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecularly tailored therapy
Number of subjects: 0
Study 31065773 — intervention group
Group type: EXPERIMENTAL
Intervention: Subxiphoid uniportal VATS lobectomy
Number of subjects: 105
Study 31065773 — intervention group
Group type: COMPARATOR
Intervention: Traditional three-port VATS lobectomy
Number of subjects: 105
Study 31065845 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to Mediterranean diet (MedDiet)
Number of subjects: 2646
Study 31065845 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of vegetables, fruits, and nuts; low intake of sugar-sweetened soft beverages
Number of subjects: 2646
Study 31065845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuts consumption
Number of subjects: 2646
Study 31066021 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide extended-release (TA-ER)
Number of subjects: 798
Study 31066021 — intervention group
Group type: COMPARATOR
Intervention: Saline-placebo
Number of subjects: 798
Study 31066678 — intervention group
Group type: EXPERIMENTAL
Intervention: Pep-Pal intervention
Number of subjects: 26
Study 31066709 — intervention group
Group type: EXPERIMENTAL
Intervention: WHOQOL-Bref questionnaire
Number of subjects: 0
Study 31066709 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12 questionnaire
Number of subjects: 0
Study 31066709 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L questionnaire
Number of subjects: 0
Study 31066709 — intervention group
Group type: EXPERIMENTAL
Intervention: iMTA Productivity Cost Questionnaire (iPCQ)
Number of subjects: 0
Study 31066709 — intervention group
Group type: EXPERIMENTAL
Intervention: iMTA Medical Consumption Questionnaire (iMCQ)
Number of subjects: 0
Study 31066709 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 0
Study 31066873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic cardiomyopathy (ICM)
Number of subjects: 11738
Study 31066873 — intervention group
Group type: COMPARATOR
Intervention: Nonischemic cardiomyopathy (NICM)
Number of subjects: 11738
Study 31066879 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of prehospital TBI guidelines emphasizing avoidance/treatment of hypoxia, prevention/correction of hyperventilation, and avoidance/treatment of hypotension
Number of subjects: 21852
Study 31066879 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of prehospital TBI guidelines
Number of subjects: 21852
Study 31067015 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric ketogenic diet (KD)
Number of subjects: 17
Study 31067240 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 50
Study 31067244 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-pocket payments after voluntary health insurance reimbursement
Number of subjects: 231
Study 31067244 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-pocket payments
Number of subjects: 231
Study 31067244 — intervention group
Group type: EXPERIMENTAL
Intervention: Kakwani index for out-of-pocket payments
Number of subjects: 231
Study 31067244 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration curves
Number of subjects: 231
Study 31067244 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient health care
Number of subjects: 231
Study 31067538 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor (PPI) treatment for 2 months
Number of subjects: 15
Study 31067538 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor (PPI) treatment
Number of subjects: 15
Study 31067538 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of PPI treatment
Number of subjects: 15
Study 31067570 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived HCMV-specific cytotoxic T cells (CTLs) as first-line therapy
Number of subjects: 0
Study 31068222 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX regimen (intravenous infusion of oxaliplatin, 65 mg/m2)
Number of subjects: 65
Study 31068369 — intervention group
Group type: EXPERIMENTAL
Intervention: STM 434 (0.25 mg/kg every 4 weeks to 8 mg/kg every 2 weeks)
Number of subjects: 32
Study 31068369 — intervention group
Group type: EXPERIMENTAL
Intervention: STM 434
Number of subjects: 32
Study 31068370 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered DNA damage repair (DDR) genes
Number of subjects: 357
Study 31068370 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with altered DDR genes
Number of subjects: 357
Study 31068479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral nonstenotic carotid plaques
Number of subjects: 777
Study 31068479 — intervention group
Group type: COMPARATOR
Intervention: No ipsilateral nonstenotic carotid plaques
Number of subjects: 777
Study 31068479 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 777
Study 31069056 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 31069056 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapies
Number of subjects: 0
Study 31069056 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative therapies
Number of subjects: 0
Study 31069128 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis with plasmin
Number of subjects: 0
Study 31069128 — intervention group
Group type: COMPARATOR
Intervention: rtPA
Number of subjects: 0
Study 31069128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31070112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy (DAPT)
Number of subjects: 0
Study 31070112 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31070470 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian system influence on VEF
Number of subjects: 21
Study 31070470 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian system influence on malondialdehyde adducts
Number of subjects: 21
Study 31070470 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian system influence on endothelin-1
Number of subjects: 21
Study 31070470 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian system influence on blood pressure
Number of subjects: 21
Study 31070711 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-energy diet for 8 weeks followed by 4 weeks of refeeding
Number of subjects: 95
Study 31070711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketosis (measured by plasma concentration of β-hydroxybutyrate)
Number of subjects: 95
Study 31070711 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-energy diet
Number of subjects: 95
Study 31070711 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (WL)
Number of subjects: 95
Study 31070733 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total iodine (StI)
Number of subjects: 1686
Study 31070733 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum non-protein-bound iodine (SnbI)
Number of subjects: 1686
Study 31070733 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake
Number of subjects: 1686
Study 31071145 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven continuous quality improvement interventions (CQI) for optimal prevention of mother-to-child transmission (PMTCT) of HIV
Number of subjects: 1377
Study 31071684 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term variation (STV)
Number of subjects: 0
Study 31071684 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate increase across one interbeat interval of phase rectified averaged signal - acceleration capacity (ACst1)
Number of subjects: 0
Study 31071684 — intervention group
Group type: EXPERIMENTAL
Intervention: Scale 4 multi-scale entropy (MSE4)
Number of subjects: 0
Study 31071684 — intervention group
Group type: EXPERIMENTAL
Intervention: Skewness
Number of subjects: 0
Study 31071684 — intervention group
Group type: EXPERIMENTAL
Intervention: Lempel Ziv complexity (LZC)
Number of subjects: 0
Study 31072155 — intervention group
Group type: EXPERIMENTAL
Intervention: AOS speakers
Number of subjects: 24
Study 31072394 — intervention group
Group type: EXPERIMENTAL
Intervention: Future therapeutic HIV vaccine
Number of subjects: 220
Study 31072581 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Life Support (ECLS)
Number of subjects: 0
Study 31072582 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 0
Study 31072582 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31072845 — intervention group
Group type: EXPERIMENTAL
Intervention: NCVC-CS1 (honeycomb microporous covered stent)
Number of subjects: 12
Study 31072858 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical training programme for practising obstetrician gynaecologist specialists
Number of subjects: 4
Study 31072858 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical training programme
Number of subjects: 4
Study 31073022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine and Ofatumumab
Number of subjects: 21
Study 31073119 — intervention group
Group type: EXPERIMENTAL
Intervention: DLPFC transcriptome analysis in schizophrenia
Number of subjects: 189
Study 31073119 — intervention group
Group type: COMPARATOR
Intervention: Control group (206 matched controls)
Number of subjects: 189
Study 31073292 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise as add-on treatment, details on dosage and duration not available
Number of subjects: 0
Study 31073654 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) measurements pre- and post-puncture
Number of subjects: 90
Study 31073654 — intervention group
Group type: COMPARATOR
Intervention: PDPH-free patients' TCD measurements
Number of subjects: 90
Study 31073959 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 185
Study 31073959 — intervention group
Group type: COMPARATOR
Intervention: Standard three-port laparoscopic cholecystectomy (LC)
Number of subjects: 185
Study 31074004 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal gluten peptides testing
Number of subjects: 64
Study 31074004 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 64
Study 31074004 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue transglutaminase antibody levels
Number of subjects: 64
Study 31074004 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian assessment
Number of subjects: 64
Study 31074220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 31074220 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 31075167 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB) scale
Number of subjects: 402
Study 31075167 — intervention group
Group type: COMPARATOR
Intervention: Baseline characteristics, GRACE, and TIMI risk scores
Number of subjects: 402
Study 31075217 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE) imaging
Number of subjects: 15
Study 31075309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 31075618 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proANP
Number of subjects: 42
Study 31075618 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT
Number of subjects: 42
Study 31075618 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 42
Study 31075727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense epirubicin, paclitaxel and cyclophosphamide (EPC)
Number of subjects: 1318
Study 31075727 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense epirubicin, cyclophosphamide, paclitaxel and capecitabine (EC-PwX)
Number of subjects: 1318
Study 31075727 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1-positive immune cells in TNBC
Number of subjects: 1318
Study 31075727 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 expression
Number of subjects: 1318
Study 31075769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty (CDA)
Number of subjects: 0
Study 31075771 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible 5-ALA fluorescence
Number of subjects: 22
Study 31075771 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative PpIX analysis
Number of subjects: 22
Study 31076139 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography measurements by seven sonographers (n = 350 echocardiograms measured)
Number of subjects: 25000
Study 31076139 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic acquisition by four sonographers (n = 176 acquisitions and measures)
Number of subjects: 25000
Study 31076409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lenalidomide 10 mg daily starting on day 9 of cycle 1 and IV rituximab 375 mg/m2
Number of subjects: 0
Study 31076416 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes (IGT or IFG) after revascularization, optimal medical therapy, or both
Number of subjects: 101
Study 31076416 — intervention group
Group type: COMPARATOR
Intervention: Normal glycemic status
Number of subjects: 101
Study 31076448 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8 T-cells from CLL patients
Number of subjects: 0
Study 31076448 — intervention group
Group type: COMPARATOR
Intervention: Control CD8 T-cells (not specified if from healthy individuals or other sources)
Number of subjects: 0
Study 31076474 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitative endovascular balloon occlusion of the aorta (REBOA) procedure
Number of subjects: 10
Study 31076762 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic laser ablation (SLA)
Number of subjects: 100
Study 31077039 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose α-tocopherol, N-acetylcysteine, and α-lipoic acid in combination
Number of subjects: 13
Study 31077164 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with platinum-doublet chemotherapy
Number of subjects: 987
Study 31077265 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 10 (IL-10) measured in serum samples
Number of subjects: 0
Study 31077265 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 10 (IL-10)
Number of subjects: 0
Study 31077529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (continuous subcutaneous insulin infusion for 7 days)
Number of subjects: 21
Study 31077529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 21
Study 31077529 — intervention group
Group type: COMPARATOR
Intervention: Control group (nondiabetics)
Number of subjects: 21
Study 31077579 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA levels increasing (0.5 to 4.0 cmH2O)
Number of subjects: 14
Study 31077579 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA levels decreasing
Number of subjects: 14